Drug Trial Radar · NCT06567769
Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9
Planned (sponsor's estimate)
Start
Nov 21, 2024
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- GC Biopharma CorpIndustry
- Sponsor type
- Industry
- First posted
- Aug 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).
Conditions
- Sanfilippo Syndrome Type A
Interventions
GC1130ADrug
ICV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidences and characteristics of adverse eventsTime frame: up to 108 weeks
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital
Oakland, California
University of Minnesota
Minneapolis, Minnesota
Samsung Medical Center
Seoul, South Korea
Ajou University Medical Center
Suwon, Gyeongi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.